Affects reproductive-age females with regular, ovulatory menstrual cycles (peak incidence in late 20s to late 30s).
Risk Factors:
Personal or family history of major depressive disorder (MDD), postpartum depression, or generalized anxiety disorder (GAD).
High psychosocial stress.
Pathophysiology: Normal cyclic ovarian steroid fluctuations (estrogen/progesterone) triggering an abnormal central serotonergic and GABAergic response in genetically vulnerable individuals.
Clinical Features
Temporal Pattern (Diagnostic Hallmark):
Symptoms arise during the luteal phase (1–2 weeks prior to menses).
Symptoms resolve rapidly within 1–4 days after onset of menses.
Must be followed by a completely symptom-free follicular phase.
Decreased interest in usual activities (anhedonia), fatigue, lethargy.
Subjective difficulty in concentration.
Changes in appetite, specific food cravings (carbohydrates).
Sleep disturbance (insomnia or hypersomnia), feeling overwhelmed.
Physical / Somatic Symptoms:
Abdominal bloating and water retention.
Breast tenderness / mastalgia.
Headaches, joint/muscle pain, weight gain.
Premenstrual Dysphoric Disorder (PMDD):
Severe variant of PMS meeting DSM-5 criteria: ≥5 symptoms during the luteal phase (with ≥1 core affective symptom: mood lability, irritability, depressed mood, anxiety) causing significant functional impairment in social, occupational, or school domains.
Diagnosis
Initial & Confirmatory / Gold Standard:
Prospective Daily Symptom Diary (e.g., Daily Record of Severity of Problems [DRSP]) tracked over ≥2 consecutive menstrual cycles. c
Confirms symptom occurrence strictly restricted to the luteal phase with resolution in the follicular phase.
Key Labs (To Exclude Organic Mimics):
Serum TSH: Rule out thyroid dysfunction.
Urine β-hCG: Rule out pregnancy.
CBC: Rule out chronic anemia if fatigue is prominent.
Note: Serum estrogen, progesterone, FSH, and LH levels are normal and not diagnostically useful.
Imaging & Biopsy: Not indicated.
Differential Diagnostics
Major Depressive Disorder (MDD) / GAD:
Diff by persistent, continuous symptoms throughout the entire cycle (no symptom-free follicular phase).
Premenstrual Exacerbation (PME) of Underlying Mood Disorder:
Diff by baseline depressive/anxious symptoms present throughout the follicular phase that merely worsen during the luteal phase.
Hypothyroidism:
Diff by non-cyclic chronic fatigue, constipation, cold intolerance, weight gain, and elevated TSH.
Perimenopause:
Diff by age typically >40–45, irregular cycle lengths (oligomenorrhea), hot flashes/vasomotor instability, and elevated FSH.
Dysmenorrhea / Endometriosis:
Diff by severe pelvic/lower abdominal cramping occurring with or during menses (or chronic cyclic pelvic pain/dyspareunia) without prominent luteal-phase neurovegetative/affective symptoms.
Can be administered continuously (daily) OR luteal-phase only (started on day 14 of cycle and discontinued at menses onset).
Rapid onset of action for PMDD (hours to days, unlike the 4–6 weeks required for MDD).
Non-Pharmacologic Adjuncts: Aerobic exercise, stress management, regular sleep hygiene, reduction of caffeine and alcohol.
Second-Line / Alternative Pharmacotherapy:
Combined Oral Contraceptives (COCs): Formulations containing Drospirenone (anti-androgenic/anti-mineralocorticoid progestin) or continuous-dose COCs to suppress the hypothalamic-pituitary-ovarian (HPO) axis and ovulation.
Alternative antidepressant: SNRIs (e.g., Venlafaxine).
Refractory Cases:
GnRH Agonists (e.g., Leuprolide) to induce chemical menopause (suppress ovulation) + low-dose estrogen/progestin “add-back” therapy to prevent osteoporosis and vasomotor symptoms.
Bilateral Salpingo-Oophorectomy (BSO): Definitive surgical option; strictly reserved for severe, incapacitating PMDD refractory to all medical interventions in women who have completed childbearing.
Complications
Severe interpersonal, family, and marital conflict.
Occupational impairment and lost productivity.
Increased risk of suicidal ideation and behavior in severe PMDD.
Progression to or unmasking of underlying major mood and anxiety disorders.